Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US8629248B2 · kind B2 · utility
21Cited by
23References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 28, 2010 |
| Grant date | Jan 14, 2014 |
| Priority date | — |
| Expiry date | May 28, 2030 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/802
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.